Gilead Sciences Files 2024 10-K
Ticker: GILD · Form: 10-K · Filed: 2025-02-28T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, biotech
TL;DR
Gilead dropped its 2024 10-K. Check financials & risks.
AI Summary
Gilead Sciences, Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Foster City, California, operates in the biological products sector. This filing provides a comprehensive overview of its financial performance, business operations, and risk factors for the period.
Why It Matters
This 10-K filing is crucial for investors and analysts to understand Gilead's financial health, strategic direction, and potential risks as of the end of the 2024 fiscal year.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Gilead faces inherent risks related to drug development, regulatory approvals, market competition, and patent expirations.
Key Numbers
- 2024 — Fiscal Year (The period covered by the 10-K filing.)
- 125 — Document Count (Number of documents included in the filing package.)
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Filer and subject of the report
- Foster City, CA (location) — Company headquarters
- 2024-12-31 (date) — Fiscal year end
- 2025-02-28 (date) — Filing date
FAQ
What is Gilead Sciences' primary business classification?
Gilead Sciences, Inc. is classified under the Standard Industrial Classification code 2836 for Biological Products (no diagnostic substances).
When was the company's fiscal year end?
The company's fiscal year ends on December 31st.
What is the SEC file number for Gilead Sciences?
The SEC file number for Gilead Sciences is 000-19731.
Where is Gilead Sciences headquartered?
Gilead Sciences is headquartered at 333 Lakeside Dr, Foster City, CA 94404.
What is the accession number for this 10-K filing?
The accession number for this 10-K filing is 0000882095-25-000006.
From the Filing
0000882095-25-000006.txt : 20250228 0000882095-25-000006.hdr.sgml : 20250228 20250228162103 ACCESSION NUMBER: 0000882095-25-000006 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 125 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250228 DATE AS OF CHANGE: 20250228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 25690602 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 10-K 1 gild-20241231.htm FORM 10-K gild-20241231 0000882095 2024 FY false http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost P1M http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent P3Y P3Y iso4217:USD xbrli:shares iso4217:USD xbrli:shares gild:country gild:segment xbrli:pure iso4217:EUR gild:program gild:designee gild:agreement gild:patent gild:claim gild:lawsuit gild:plaintiff 0000882095 2024-01-01 2024-12-31 0000882095 2024-06-28 0000882095 2025-02-21 0000882095 2024-12-31 0000882095 2023-12-31 0000882095 us-gaap:ProductMember 2024-01-01 2024-12-31 0000882095 us-gaap:ProductMember 2023-01-01 2023-12-31 0000882095 us-gaap:ProductMember 2022-01-01 2022-12-31 0000882095 gild:RoyaltyContractAndOtherMember 2024-01-01 2024-12-31 0000882095 gild:RoyaltyContractAndOtherMember 2023-01-01 2023-12-31 0000882095 gild:RoyaltyContractAndOtherMember 2022-01-01 2022-12-31 0000882095 2023-01-01 2023-12-31 0000882095 2022-01-01 2022-12-31 0000882095 us-gaap:CommonStockMember 2021-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000882095 us-gaap:RetainedEarningsMember 2021-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2021-12-31 0000882095 2021-12-31 0000882095 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000882095 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000882095 us-gaap:CommonStockMember 2022-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000882095 us-gaap:RetainedEarningsMember 2022-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2022-12-31 0000882095 2022-12-31 0000882095 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000882095 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000882095 us-gaap:CommonStockMember 2023-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000882095 us-gaap:Ret